お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
957672

世界のCAR-T細胞療法市場

CAR T-cell Therapy

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 112 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

世界のCAR-T細胞療法市場
出版日: 2020年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 112 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のCAR-T細胞療法の市場規模は、分析期間(2020年~2027年)に57.7%のCAGRで成長する見通しで、2020年の3億4,070万米ドルから2027年には83億米ドルに達すると予測されています。当レポートで分析されているセグメントの1つであるCD19は、分析期間中に49.9%の年率で成長し、40億米ドルに達すると予測されています。

当レポートは、世界のCAR-T細胞療法市場について調査しており、市場シェア、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • 競合の市場シェア
    • 競合の市場シェアシナリオ
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • プロファイルされた企業の総数:46社
目次
Product Code: MCP10884

Global CAR T-cell Therapy Market to Reach $8.3 Billion by 2027

Amid the COVID-19 crisis, the global market for CAR T-cell Therapy estimated at US$340.7 Million in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at aCAGR of 57.7% over the period 2020-2027. CD19, one of the segments analyzed in the report, is projected to record 49.9% CAGR and reach US$4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the CD22 segment is readjusted to a revised 70.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $103.7 Million, While China is Forecast to Grow at 55.2% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$103.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 55.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50.7% and 49.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 39.1% CAGR.We bring years of research experience to this 7th edition of our report. The 112-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Competitor Market Shares
    • CAR T-cell Therapy Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 2: World 7-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for CD19 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 4: World 7-Year Perspective for CD19 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for CD22 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 6: World 7-Year Perspective for CD22 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US CAR T-cell Therapy Market Share (in %) by Company: 2019 & 2025
    • Market Analytics
    • TABLE 7: USA Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 8: USA 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • CANADA
    • TABLE 9: Canada Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 10: Canada 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • JAPAN
    • TABLE 11: Japan Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 12: Japan 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • CHINA
    • TABLE 13: China Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 14: China 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • EUROPE
    • Market Facts & Figures
    • European CAR T-cell Therapy Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • Market Analytics
    • TABLE 15: Europe Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
    • TABLE 16: Europe 7-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 17: Europe Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 18: Europe 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • FRANCE
    • TABLE 19: France Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 20: France 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • GERMANY
    • TABLE 21: Germany Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 22: Germany 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • ITALY
    • TABLE 23: Italy Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 24: Italy 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 25: UK Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 26: UK 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 27: Rest of Europe Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 28: Rest of Europe 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 29: Asia-Pacific Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 30: Asia-Pacific 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 31: Rest of World Current & Future Analysis for CAR T-cell Therapy by Antigen - CD19 and CD22 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
    • TABLE 32: Rest of World 7-Year Perspective for CAR T-cell Therapy by Antigen - Percentage Breakdown of Value Sales for CD19 and CD22 for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.